Naslov
Finding new analytical solutions for personalized breast cancer treatment

Autori
Sertić, Miranda ; Silovski, Tajana ; Crnković, Slaven ; Nigović, Biljana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo

Izvornik
FIP Congress of Pharmacy and Pharmaceutical Sciences 2020 / - : International Pharmaceutical Federation (FIP), 2020, 1-1

Skup
80th FIP World Pharmacy and Pharmaceutical Sciences Congress ; 22nd National Pharmaceutical Congress Spain

Mjesto i datum
Sevilla, Španjolska, 13.09.2020. - 17.09.2020

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
breast cancer, personalized medicine, bioanalysis

Sažetak
Background: Breast cancer is the most common malignant tumor in women. Systematic medication therapies include chemotherapy, endocrine therapy, targeted therapy and immunotherapy. Purpose: In clinical practice, the concept of therapeutic drug monitoring (TDM) is increasingly being used to achieve the best therapeutic effect of the drug with minimal risk of side effects or toxic effects. In oncology patients this concept is still being adapted, with only a small number of drugs (such as methotrexate) in which TDM is part of the standard of care. For many anticancer drugs there is still not enough data on the effectiveness and importance of this approach. Methods: Patient's not achieving desired treatment outcomes will be chosen for TDM. New analytical methods, employing both liquid chromatography (LC) and capillary electrophoresis (CE) coupled to a sensitive mass spectrometer (MS) and sample pre-treatment methods, will be developed to ensure accurate, fast and reliable drug determination. Results: Through this ongoing project, new analytical LC- MS and CE methods will be developed for the analysis of novel drugs, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors palbociclib and ribociclib, which are used in combination with endocrine therapy (anastrozole and letrozole) or antiestrogen fulvestrant. Conclusion: Newly developed analytical methods can be used in routine clinical laboratories for TDM of patients on these cancer treatment protocols. Additional post-marketing surveillance, PK and metabolic studies of palbociclib and ribociclib will give more insight into their pharmacokinetics in real patients with comorbidities and additional therapy.

Izvorni jezik
Engleski

Znanstvena područja
Farmacija

POVEZANOST RADA